<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>TRDMT1 on Superhyydl's Blog</title><link>https://blog.superhyydl.org/tags/trdmt1/</link><description>Recent content in TRDMT1 on Superhyydl's Blog</description><generator>Hugo</generator><language>zh-cn</language><lastBuildDate>Sun, 06 Sep 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://blog.superhyydl.org/tags/trdmt1/index.xml" rel="self" type="application/rss+xml"/><item><title>精读 | TRDMT1催化mRNA m5C修饰，通过HR修复和IRS2激活降低化疗敏感性</title><link>https://blog.superhyydl.org/reading/trdmt1-mediated-mrna-m5c-methylation-decreases-chemotherapy/</link><pubDate>Sun, 06 Sep 2026 00:00:00 +0000</pubDate><guid>https://blog.superhyydl.org/reading/trdmt1-mediated-mrna-m5c-methylation-decreases-chemotherapy/</guid><description>&lt;h2 id="一句话亮点"&gt;一句话亮点&lt;/h2&gt;
&lt;p&gt;化疗打击下，胰腺癌反手给mRNA戴上&amp;quot;m5C安全帽&amp;quot;——TRDMT1被DNA损伤唤醒，一边给IRS2打上甲基化标记激活生存信号，一边召唤RAD51等HR修复队员，硬生生把化疗的杀伤力扛了过去。&lt;/p&gt;
&lt;h2 id="背景痛点"&gt;背景/痛点&lt;/h2&gt;
&lt;p&gt;胰腺导管腺癌（PDAC）是公认的&amp;quot;癌王&amp;quot;，化疗（GEM、5-FU、奥沙利铂、伊立替康等）至今仍是基石方案，但耐药问题让疗效像一拳打在棉花上。&lt;/p&gt;
&lt;p&gt;目前关于PDAC化疗耐药的研究，大多盯着DNA层面的修复或基因组突变。但作者团队之前发现了一个有意思的现象：mRNA上的m5C甲基化像一种&amp;quot;损伤代码&amp;quot;，可能在DNA损伤部位发挥作用。不过，这个修饰在胰腺癌里到底谁在管？影响了下游哪些通路？是不是真的跟化疗耐药挂钩？这些都还是问号。&lt;/p&gt;
&lt;p&gt;&lt;img alt="Fig. 1：Global profiling of mRNA m5C methylation and transcriptional responses to chemotherapy-induced DNA damage in pancreatic cancer cells (a) Schematic of the dot blot–based workflow for global quantification of mRNA m5C. (b) Dot blot of mRNA m5C in Mia PaCa-2 and AsPC-1 cells treated with gemcitabine (GEM) or 5-fluorouracil (5-FU). (c) Total RNA m5C levels in pancreatic cancer cells following GEM or 5-FU treatment. (d) Sequence context (±10 bp) surrounding significant m5C sites; all sites (top), GEM-enriched sites (middle), and PBS-enriched sites (bottom). (e) Distribution of hyper- and hypo-methylated m5C sites (GEM vs PBS) across major mRNA regions. (f) Schematic of RNA-seq workflow for GEM-versus PBS-treated pancreatic cancer cells. (g) Expression of repre\u00ad sentative m5C regulatory genes before and after GEM treatment. (h) Volcano plot of differentially expressed genes in GEM-treated cells. (i) Heatmap of selected RNA- modification–related genes following DNA-damaging treatments. (j) Expression of TRDMT1 after H2O2, GEM, or 5-FU treatment. (k) TRDMT1 expression in TCGA pancreatic cancer tumors and adjacent normal tissues. (a) Created in BioRender. Luo, W. (2026) https://BioRender.com/6tvfcmr." loading="lazy" src="https://blog.superhyydl.org/images/reading/trdmt1-mediated-mrna-m5c-methylation-decreases-chemotherapy/figure-01.png"&gt;&lt;/p&gt;</description></item></channel></rss>